Biotoxtech Co. Ltd (086040) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotoxtech Co. Ltd (086040) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-354.72 Million ≈ $-240.39K USD) by net assets (₩34.06 Billion ≈ $23.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biotoxtech Co. Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Biotoxtech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 086040 total debt and obligations for a breakdown of total debt and financial obligations.
Biotoxtech Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotoxtech Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seoyon Topmetal Co. Ltd
KQ:019770
|
-0.023x |
|
Aligos Therapeutics Inc
NASDAQ:ALGS
|
-0.406x |
|
NextCure Inc
NASDAQ:NXTC
|
-0.265x |
|
NXT Energy Solutions Inc
TO:SFD
|
-0.086x |
|
OnKure Therapeutics, Inc.
NASDAQ:OKUR
|
-0.196x |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
0.097x |
|
Radiant Globaltech Bhd
KLSE:0202
|
0.050x |
|
Wemade Max Co. Ltd
KQ:101730
|
-0.016x |
Annual Cash Flow Conversion Efficiency for Biotoxtech Co. Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Biotoxtech Co. Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Biotoxtech Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩40.08 Billion ≈ $27.16 Million |
₩-7.12 Billion ≈ $-4.83 Million |
-0.178x | +47.23% |
| 2023-12-31 | ₩48.23 Billion ≈ $32.69 Million |
₩-16.24 Billion ≈ $-11.00 Million |
-0.337x | -1037.55% |
| 2022-12-31 | ₩44.23 Billion ≈ $29.98 Million |
₩-1.31 Billion ≈ $-887.16K |
-0.030x | -128.02% |
| 2021-12-31 | ₩41.14 Billion ≈ $27.88 Million |
₩4.35 Billion ≈ $2.95 Million |
0.106x | -22.40% |
| 2020-12-31 | ₩33.53 Billion ≈ $22.72 Million |
₩4.56 Billion ≈ $3.09 Million |
0.136x | +184.65% |
| 2019-12-31 | ₩30.19 Billion ≈ $20.46 Million |
₩1.44 Billion ≈ $978.48K |
0.048x | -51.17% |
| 2018-12-31 | ₩31.25 Billion ≈ $21.18 Million |
₩3.06 Billion ≈ $2.07 Million |
0.098x | -56.77% |
| 2017-12-31 | ₩26.59 Billion ≈ $18.02 Million |
₩6.02 Billion ≈ $4.08 Million |
0.227x | +5.24% |
| 2016-12-31 | ₩24.54 Billion ≈ $16.63 Million |
₩5.28 Billion ≈ $3.58 Million |
0.215x | +736.12% |
| 2015-12-31 | ₩23.58 Billion ≈ $15.98 Million |
₩-798.17 Million ≈ $-540.91K |
-0.034x | +55.89% |
| 2014-12-31 | ₩26.68 Billion ≈ $18.08 Million |
₩-2.05 Billion ≈ $-1.39 Million |
-0.077x | -221.95% |
| 2012-12-31 | ₩25.93 Billion ≈ $17.57 Million |
₩1.63 Billion ≈ $1.11 Million |
0.063x | -58.32% |
| 2011-12-31 | ₩21.74 Billion ≈ $14.73 Million |
₩3.28 Billion ≈ $2.22 Million |
0.151x | -- |
About Biotoxtech Co. Ltd
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and b… Read more